IROMED GROUP IS AN R&D AND MEDICAL DEVICES MANUFACTURING COMPANY. ITS MISSION IS TO DEVELOP UNIQUE AND INNOVATIVE OPHTHALMIC PRODUCTS AND SOLUTIONS FOR HEALTHCARE PROFESSIONALS.
Iromed Group develops and manufactures ophthalmic medical devices. Thanks to its strong commitment to research, Iromed develops unique and innovative ophthalmic technologies, formulations, and protocols. All Iromed products are supported by international patents and publications in top-ranked scientific journals.
Iromed Group is in partnership with SERVImed Industrial S.p.A., which manages the worldwide distribution of its products through Italian and international companies, providing continuous support to its clients.
OUR OPHTHALMIC PRODUCT LINES:
IROMED Group opens its own R&D division to start researching ophthalmic products. The company’s objective is to develop and bring to the market innovative, unique and patented products and formulations with strong scientific backing.
The development of the R&D department benefited from its research experience and the continuous support of clinical research and international publications in high impact journals. All of IROMED Group’s ophthalmic products are patented and CE marked.
In 2016, RIBOCROSS ® te, the first cross-linking solution based on Riboflavin and Vitamin E TPGS, is launched globally.
Developed with a high corneal penetration and patented formulation, RIBOCROSS ® te is the only solution that uses Vitamin E TPGS’ enhancer properties to provide high performances in every corneal cross-linking protocol. RIBOCROSS ® te is the only Riboflavin solution that can be used in the exclusive Custom fast CXL protocol.
In 2017, IROMED Group’s Ophthalmic surgical line expands with the international launch of CF X-LINKER ®, a versatile UV device for corneal cross-linking, bringing to the market the Custom Fast CXL, a customized low power EPI-ON protocol, unique to the CF X-LINKER ® device.
The cross-linking line expands with the addition of RIBOFAST, a patented dextran free solution that makes IROMED Group’s cross-linking portfolio one of the most versatile on the market.
In the same year, the eye drops line is officially opened with the launch of DROP defence ®, an anti-UV and anti-blue light protective solution, which is the first and only solution to receive the Personal Protective Equipment certification.
2019 is a year of much growth for our ophthalmic portfolio, with the launch of two new products: DROP therapeutic ®, a high quality patented solution, and DROPsept ®, a unique and patented solution with protective and repairing action.
In the same year, IROMED Group announces a partnership with TECLens for the distribution and FDA approval of a new combined product for keratoconus treatment, solidifying its international status.
Despite the uncertainty of the pandemic, Iromed managed to launch new products: REmark®, an innovative diagnostic stain based on riboflavin, and MACUoff, the company's first dietary supplement.
Between 2021 and 2022 Iromed brought new products to its ophthalmic portfolio. The surgical line saw the launch of REmark C surgical staining solution. At the same time, Ribohyal ophthalmic gel and DROPtonic 5% were added to the eye drops line, while CLARvision was launched in the supplements line.
The end of 2022 saw another milestone in the company's Global expansion, with the official launch of CF X-LINKER in the Chinese Market thanks to SERVImed Industrial.
In 2023 Iromed further expanded its ophthalmic portfolio with REmark VTR-VM (vitreoretinal stain) and the innovative Viscorib 1.0 & 1.5 colored viscoelastics.
Raffaella Broccardo | [email protected]
Marco Maria Fedeli | [email protected]
Edoardo Menna | [email protected]
Tel. +39 337 113 84 07
Rosaria Tremamunno | [email protected]
Tel. +39 348 991 4487
Andrea Napolitano | [email protected]
Tel. +39 329 4757978
Carmine Pontecorvo | [email protected]
Fabrizio Pieralisi | [email protected]
Errore: Modulo di contatto non trovato.